November 1, 2012
Geron (GERN) Q3 Highlights and Achievements
October 24, 2012
NeoStem (NYSE MKT: NBS) Detractors beware, the debate continues
October 17, 2012
StemCells (STEM) leapfrogs the "valley of death"
October 10, 2012
StemCells (STEM) Preclinical and Clinical Results of Its Neural Stem Cells for Myelination Disorder
September 28, 2012
Geron (GERN) 2 new Board Members
September 19, 2012
NeoStem (NYSE MKT: NBS) Greenmail “BS”
September 14, 2012
Neuralstem Inc. (CUR) Jumping the Gun or Fast and Furious ... Sell!
September 12, 2012
Opexa (OPXA), Secondary Progressive Multiple Sclerosis (SPMS) trial initiates
September 5, 2012
Ed Owens, Tribute to an Investment King and Legend
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.